Cumulative incidences of disease transformation to SMF or acute myeloid leukemia according to exposure to a cytoreductive agent. Cumulative incidence of SAML in PV patients (A), cumulative incidence of SMF in PV patients (B), cumulative incidence of SAML in ET patients (C), and cumulative indicence of SMF in ET patients (D).